Literature DB >> 29764827

Not so mass effect? Finding of a remarkable 'incidentaloma' in a teenager with neurofibromatosis.

Daniel John Keen1, Hannah Norman-Bruce1, Salah Mansy1.   

Abstract

A 13-year-old boy with neurofibromatosis type 1 presented to the emergency department twice in a fortnight with moderate intermittent abdominal pain, radiating to the back and associated with nausea and vomiting. He examined as a well child with a soft abdomen and minimal tenderness. A history of constipation was identified but he failed to respond to a trial of laxatives. Subsequent ultrasound abdomen demonstrated a large mass surrounding the porta hepatis. MRI further characterised a focal, non-aggressive lesion extending from his liver, encapsulating his pancreas, portal vessels and laterally displacing his spleen and left kidney. Biopsy performed at a specialist cancer treatment hospital of our reference later confirmed this to be a benign neurofibroma of a size not previously reported in the literature. He will be managed conservatively with surveillance imaging and the potential for chemotherapy should the lesion continue to grow. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  congenital disorders; paediatrics; radiology

Mesh:

Year:  2018        PMID: 29764827      PMCID: PMC5961541          DOI: 10.1136/bcr-2018-224174

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Intestinal plexiform neurofibromas.

Authors:  L Calligaris; F Marchetti; A Ventura
Journal:  Dig Liver Dis       Date:  2008-02-21       Impact factor: 4.088

2.  Intrahepatic plexiform neurofibroma with neurofibromatosis type 1.

Authors:  Yoshiki Kusama; Yo Matsui
Journal:  Pediatr Int       Date:  2018-01       Impact factor: 1.524

3.  Diffuse, retroperitoneal mesenteric and intrahepatic periportal plexiform neurofibroma in a 5-year-old boy.

Authors:  L Z Fenton; N Foreman; J Wyatt-Ashmead
Journal:  Pediatr Radiol       Date:  2001-09

4.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Authors:  Eva Dombi; Andrea Baldwin; Leigh J Marcus; Michael J Fisher; Brian Weiss; AeRang Kim; Patricia Whitcomb; Staci Martin; Lindsey E Aschbacher-Smith; Tilat A Rizvi; Jianqiang Wu; Rachel Ershler; Pamela Wolters; Janet Therrien; John Glod; Jean B Belasco; Elizabeth Schorry; Alessandra Brofferio; Amy J Starosta; Andrea Gillespie; Austin L Doyle; Nancy Ratner; Brigitte C Widemann
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

Review 5.  Neurofibromatosis.

Authors:  Andrea I McClatchey
Journal:  Annu Rev Pathol       Date:  2007       Impact factor: 23.472

6.  Massive plexiform neurofibromas in childhood: natural history and management issues.

Authors:  Demitre Serletis; Patricia Parkin; Eric Bouffet; Manohar Shroff; James M Drake; James T Rutka
Journal:  J Neurosurg       Date:  2007-05       Impact factor: 5.115

7.  MRI features of plexiform neurofibromas involving the liver and pancreas in children with neurofibromatosis type 1.

Authors:  Jorge Delgado; Diego Jaramillo; Victor Ho-Fung; Michael J Fisher; Sudha A Anupindi
Journal:  Clin Radiol       Date:  2014-03-01       Impact factor: 2.350

8.  Diagnosis and management of an isolated pediatric plexiform neurofibroma involving the hepatic and celiac plexus using multimodality approach: problem solving with diffusion-weighted magnetic resonance imaging.

Authors:  Merel M Scheurkogel; June Koshy; Kenneth J Cohen; Thierry A G M Huisman; Thangamadhan Bosemani
Journal:  European J Pediatr Surg Rep       Date:  2013-04-24

9.  Neurofibromatosis type 1 presenting with plexiform neurofibromas in two patients: MRI features.

Authors:  Ahmet Mesrur Halefoglu
Journal:  Case Rep Med       Date:  2012-09-20

Review 10.  Neurofibromatosis.

Authors:  P A Gerber; A S Antal; N J Neumann; B Homey; C Matuschek; M Peiper; Wilfried Budach; E Bölke
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.